AI Engines For more Details: Perplexity Kagi Labs You
Allergy Relief: Pheniramine maleate works by blocking the effects of histamine, a substance in the body that triggers allergic symptoms. It helps alleviate symptoms such as sneezing, itching, watery eyes, and runny nose associated with allergic reactions to pollen, dust, animal dander, and other allergens.
Nasal Congestion: Pheniramine can help reduce nasal congestion by decreasing inflammation and swelling of the nasal passages, making it easier to breathe.
Relief of Itching: It has anti-itching properties and can relieve itching associated with allergic skin conditions like hives (urticaria) or insect bites.
Management of Allergic Conjunctivitis: Pheniramine can alleviate symptoms of allergic conjunctivitis, including redness, itching, and tearing of the eyes.
Sedation: Pheniramine has sedating effects and is sometimes used in over-the-counter combination products to relieve symptoms of the common cold or flu, particularly at nighttime. It can help promote sleep and alleviate symptoms such as cough and congestion.
Motion Sickness: Pheniramine may be used to prevent motion sickness and alleviate symptoms such as nausea and vomiting associated with travel.
Side Effects: Common side effects of pheniramine maleate include drowsiness, dry mouth, blurred vision, constipation, and urinary retention. These side effects are usually mild and may diminish with continued use or dose adjustment.
Avoiding Alcohol: Patients taking pheniramine should avoid consuming alcohol, as it can increase the sedative effects of the medication and impair cognitive function.
Interactions: Pheniramine may interact with other medications, including central nervous system depressants, anticholinergic drugs, and monoamine oxidase inhibitors (MAOIs). Patients should inform their healthcare provider about all medications they are taking to avoid potential drug interactions.
Caution in Certain Populations: Pheniramine should be used with caution in elderly patients, who may be more sensitive to its sedative effects, and in individuals with certain medical conditions such as glaucoma, urinary retention, or prostate enlargement.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.3 | -0.3 | |
ADHD | 1.8 | 0 | 0 |
Age-Related Macular Degeneration and Glaucoma | 0.2 | 0.1 | 1 |
Allergic Rhinitis (Hay Fever) | 1 | 1.3 | -0.3 |
Allergies | 3.3 | 1.4 | 1.36 |
Allergy to milk products | 1 | 0.5 | 1 |
Alopecia (Hair Loss) | 0.9 | 0.9 | |
Alzheimer's disease | 1.6 | 2.8 | -0.75 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.6 | 0.6 | 1.67 |
Ankylosing spondylitis | 2.2 | 0.3 | 6.33 |
Anorexia Nervosa | 0.1 | 1.1 | -10 |
Antiphospholipid syndrome (APS) | 0.8 | 0.8 | |
Asthma | 0.8 | 0.7 | 0.14 |
Atherosclerosis | 0.8 | 1.2 | -0.5 |
Atrial fibrillation | 1.5 | 0.6 | 1.5 |
Autism | 4.8 | 4.4 | 0.09 |
Barrett esophagus cancer | 0.5 | 0.2 | 1.5 |
benign prostatic hyperplasia | 0.2 | 0.2 | |
Bipolar Disorder | 0.4 | 0.6 | -0.5 |
Brain Trauma | 0.7 | 0.3 | 1.33 |
Carcinoma | 1.8 | 1.5 | 0.2 |
Celiac Disease | 1.3 | 2.1 | -0.62 |
Cerebral Palsy | 1.5 | 0.6 | 1.5 |
Chronic Fatigue Syndrome | 1.9 | 2.5 | -0.32 |
Chronic Kidney Disease | 0.5 | 0.7 | -0.4 |
Chronic Lyme | 0.3 | -0.3 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.9 | 0.2 | 3.5 |
Chronic Urticaria (Hives) | 1.6 | 0.7 | 1.29 |
Coagulation / Micro clot triggering bacteria | 0.7 | 0.6 | 0.17 |
Colorectal Cancer | 1.8 | 0.7 | 1.57 |
Constipation | 0.4 | 0.5 | -0.25 |
Coronary artery disease | 0.6 | 0.8 | -0.33 |
COVID-19 | 6.4 | 4.7 | 0.36 |
Crohn's Disease | 3.9 | 2.4 | 0.63 |
cystic fibrosis | 0.5 | 0.6 | -0.2 |
deep vein thrombosis | 0.5 | 0.3 | 0.67 |
Depression | 4.5 | 4.7 | -0.04 |
Dermatomyositis | 0.2 | 0.3 | -0.5 |
Eczema | 0.7 | 1.3 | -0.86 |
Endometriosis | 1.5 | 0.7 | 1.14 |
Eosinophilic Esophagitis | 0 | 0.5 | 0 |
Epilepsy | 2.1 | 1.4 | 0.5 |
Fibromyalgia | 1.6 | 1 | 0.6 |
Functional constipation / chronic idiopathic constipation | 2.6 | 1.6 | 0.63 |
gallstone disease (gsd) | 1.6 | 0.4 | 3 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1 | 0.8 | 0.25 |
Generalized anxiety disorder | 0.9 | 1.3 | -0.44 |
giant cell arteritis | 0.5 | -0.5 | |
Glioblastoma | 0.2 | -0.2 | |
Gout | 0 | 0 | |
Graves' disease | 1 | 1 | 0 |
Halitosis | 0.6 | 0.2 | 2 |
Hashimoto's thyroiditis | 1.1 | 0.4 | 1.75 |
Hidradenitis Suppurativa | 0.2 | 0.5 | -1.5 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.8 | 0.3 | 5 |
hypercholesterolemia (High Cholesterol) | 0.7 | 0.3 | 1.33 |
hyperglycemia | 0.2 | 1.2 | -5 |
Hyperlipidemia (High Blood Fats) | 0.9 | 0.5 | 0.8 |
hypersomnia | 0.3 | -0.3 | |
hypertension (High Blood Pressure | 1.4 | 3.1 | -1.21 |
Hypothyroidism | 0.6 | -0.6 | |
Hypoxia | 0.4 | 0.4 | |
IgA nephropathy (IgAN) | 1.2 | -1.2 | |
Inflammatory Bowel Disease | 2.3 | 3.7 | -0.61 |
Insomnia | 0.6 | 0.3 | 1 |
Intelligence | 0.6 | 0.6 | |
Intracranial aneurysms | 0.5 | 0.5 | 0 |
Irritable Bowel Syndrome | 2.6 | 1.6 | 0.63 |
Liver Cirrhosis | 2.7 | 1.9 | 0.42 |
Long COVID | 3.3 | 4.6 | -0.39 |
Low bone mineral density | 0.2 | -0.2 | |
Lung Cancer | 0.3 | 0.7 | -1.33 |
ME/CFS with IBS | 0.7 | 1.2 | -0.71 |
ME/CFS without IBS | 0.9 | 0.6 | 0.5 |
Menopause | 1.1 | 1.1 | |
Metabolic Syndrome | 4.5 | 4.6 | -0.02 |
Mood Disorders | 7.2 | 4.7 | 0.53 |
multiple chemical sensitivity [MCS] | 0.8 | 0.3 | 1.67 |
Multiple Sclerosis | 2.1 | 2.5 | -0.19 |
Multiple system atrophy (MSA) | 1.3 | 0.6 | 1.17 |
Neuropathy (all types) | 0.6 | 0.2 | 2 |
neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.7 | 2.9 | -0.71 |
NonCeliac Gluten Sensitivity | 0.3 | -0.3 | |
Obesity | 4.6 | 2 | 1.3 |
obsessive-compulsive disorder | 3 | 1.4 | 1.14 |
Osteoarthritis | 1.3 | 1.3 | |
Osteoporosis | 1.3 | 0.7 | 0.86 |
pancreatic cancer | 0.3 | 0.3 | |
Parkinson's Disease | 1.8 | 1.8 | 0 |
Polycystic ovary syndrome | 1.3 | 1.2 | 0.08 |
Postural orthostatic tachycardia syndrome | 0.5 | 0.3 | 0.67 |
Premenstrual dysphoric disorder | 1 | 0.1 | 9 |
primary biliary cholangitis | 0.1 | 0.5 | -4 |
Psoriasis | 3.7 | 0.7 | 4.29 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.1 | 2.7 | 0.15 |
Rosacea | 0.3 | 0.6 | -1 |
Schizophrenia | 5 | 1.2 | 3.17 |
scoliosis | 0 | 0.1 | 0 |
Sjögren syndrome | 2.3 | 1.6 | 0.44 |
Sleep Apnea | 0.6 | 0.6 | 0 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.5 | 0.4 | 0.25 |
Stress / posttraumatic stress disorder | 1.7 | 1.3 | 0.31 |
Systemic Lupus Erythematosus | 2 | 0.9 | 1.22 |
Tic Disorder | 0.3 | 0.8 | -1.67 |
Tourette syndrome | 0.2 | 0.1 | 1 |
Type 1 Diabetes | 1.6 | 1.6 | 0 |
Type 2 Diabetes | 4.1 | 3.4 | 0.21 |
Ulcerative colitis | 1.9 | 2 | -0.05 |
Unhealthy Ageing | 1.9 | 0.8 | 1.37 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.